Sponsor

Bial - Portela C S.A.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Bial - Portela C S.A. appears in 79 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials79
Recruiting shown1
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world TreatmentNCT07145190 · lead sponsor · 2025-08-27
RECRUITING
REal-life ON PARKinson's - ITaly (REONPARK-IT)NCT07403799 · lead sponsor · 2025-07-08
ACTIVE_NOT_RECRUITING
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.NCT04990284 · lead sponsor · 2021-11-29
COMPLETED
OpicApone Sleep dISorderNCT04986995 · lead sponsor · 2021-06-09
COMPLETED
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)NCT04978597 · lead sponsor · 2021-05-31
COMPLETED
OpiCapone Effect on Motor Fluctuations and pAiNNCT04986982 · lead sponsor · 2021-02-25
COMPLETED
Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's DiseaseNCT03959540 · lead sponsor · 2020-04-28
COMPLETED
Safety and Efficacy of BIA 5-1058 in PAHNCT06009185 · lead sponsor · 2019-06-26
COMPLETED
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)NCT04316143 · lead sponsor · 2019-06-03
COMPLETED
Relative Bioavailability and Bioequivalence of OpicaponeNCT03820037 · lead sponsor · 2019-03-19
COMPLETED
Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and FurosemideNCT07173738 · lead sponsor · 2018-06-11
COMPLETED
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058NCT03708146 · lead sponsor · 2018-05-28
COMPLETED
Effect of BIA 5 1058 on Cardiac RepolarizationNCT03489005 · lead sponsor · 2018-04-09
COMPLETED
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of SildenafilNCT04994860 · lead sponsor · 2018-03-22
COMPLETED
Effect of BIA 5-1058 on the Steady State Pharmacokinetics of TreprostinilNCT04675944 · lead sponsor · 2018-02-28
COMPLETED
Effect of BIA 5-1058 400 mg on Warfarin PharmacokineticsNCT04994119 · lead sponsor · 2018-02-23
COMPLETED
Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)NCT04265027 · lead sponsor · 2018-02-20
COMPLETED
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of BosentanNCT04991207 · lead sponsor · 2018-02-06
COMPLETED
Bioavailability and Bioequivalence Study of Two Different Sources of OpicaponeNCT03116295 · lead sponsor · 2017-06-20
COMPLETED
Absorption, Distribution, Metabolism and Excretion of BIA 5-1058NCT04991181 · lead sponsor · 2017-03-31
COMPLETED
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067NCT03119194 · lead sponsor · 2017-01-27
COMPLETED
Efficacy and Safety of Opicapone in Clinical PracticeNCT02847442 · lead sponsor · 2016-11-23
COMPLETED
Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058NCT04991194 · lead sponsor · 2015-10-12
TERMINATED
Effect of Food on BIA 5-1058NCT04991155 · lead sponsor · 2015-07-20
COMPLETED
Effect of Food on OpicaponeNCT03116308 · lead sponsor · 2014-11-21
COMPLETED
Effect of Opicapone at Steady State on Warfarin PharmacokineticsNCT02305030 · lead sponsor · 2014-03-01
COMPLETED
Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy VolunteersNCT02305017 · lead sponsor · 2014-03-01
COMPLETED
Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of OpicaponeNCT02305316 · lead sponsor · 2014-02-01
COMPLETED
The Effect of BIA 9-1067 at Steady-state on the Levodopa PharmacokineticsNCT02170376 · lead sponsor · 2011-09-01
COMPLETED
Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsNCT01520987 · lead sponsor · 2011-05-01
COMPLETED
Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.NCT02151994 · lead sponsor · 2011-03-01
COMPLETED
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and MetabolitesNCT02169427 · lead sponsor · 2011-03-01
COMPLETED
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonNCT01568073 · lead sponsor · 2011-03-01
COMPLETED
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.NCT01227655 · lead sponsor · 2011-03-01
COMPLETED
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic PainNCT01129960 · lead sponsor · 2010-11-01
TERMINATED
Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and WomenNCT01532115 · lead sponsor · 2010-05-01
COMPLETED
Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic ImpairmentNCT02101190 · lead sponsor · 2010-03-01
COMPLETED
Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) PatientsNCT01568047 · lead sponsor · 2010-02-01
COMPLETED
Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa PharmacokineticsNCT02169414 · lead sponsor · 2010-02-01
COMPLETED
Effect of BIA 9-1067 on Rasagiline PharmacokineticsNCT01532128 · lead sponsor · 2009-11-01
COMPLETED
Study of BIA 9-1067 to Investigate Its Effect on Levodopa PharmacokineticNCT01519284 · lead sponsor · 2009-11-01
COMPLETED
Effect of Rasagiline on BIA 9-1067 PharmacokineticsNCT01532141 · lead sponsor · 2009-11-01
COMPLETED
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of WarfarinNCT02169440 · lead sponsor · 2009-06-01
COMPLETED
Effect of BIA 9-1067 on the Pharmacokinetics of RepaglinideNCT01536366 · lead sponsor · 2009-06-01
COMPLETED
Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and MetabolitesNCT01515891 · lead sponsor · 2009-05-01
COMPLETED
A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067NCT01568034 · lead sponsor · 2009-04-01
COMPLETED
Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/CarbidopaNCT01533077 · lead sponsor · 2009-03-01
COMPLETED
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/BenserazideNCT01533116 · lead sponsor · 2009-03-01
COMPLETED
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/BenserazideNCT02169466 · lead sponsor · 2009-01-01
COMPLETED
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/CarbidopaNCT02169453 · lead sponsor · 2008-10-01
COMPLETED
Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young SubjectsNCT02092168 · lead sponsor · 2008-10-01
COMPLETED
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/CarbidopaNCT02169479 · lead sponsor · 2008-09-01
COMPLETED
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/BenserazideNCT02169895 · lead sponsor · 2008-09-01
COMPLETED
Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and MetabolitesNCT03014375 · lead sponsor · 2008-09-01
COMPLETED
Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453NCT03099226 · lead sponsor · 2008-07-15
COMPLETED
Bioavailability Study of BIA 5-453NCT03090568 · lead sponsor · 2008-07-15
COMPLETED
Pharmacokinetics of BIA 5-453 and Its MetabolitesNCT03090724 · lead sponsor · 2008-06-13
COMPLETED
Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067NCT02071810 · lead sponsor · 2008-04-01
COMPLETED
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic NeuropathyNCT00980746 · lead sponsor · 2007-11-01
COMPLETED
A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male SubjectsNCT01520727 · lead sponsor · 2007-10-01
COMPLETED

Drugs studied in this sponsor's trials

16 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Bial - Portela C S.A. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
entacapone3
opicapone3
opicapone 50 MG3
warfarin3
carbidopa2
levodopa2
rasagiline2
bosentan1
entacapone RxCUI 60307 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials opicapone RxCUI 2362167 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials opicapone 50 MG RxCUI 2362179 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials warfarin RxCUI 11289 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials carbidopa RxCUI 2019 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials levodopa RxCUI 6375 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials rasagiline RxCUI 134748 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials bosentan RxCUI 75207 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial eslicarbazepine acetate RxCUI 1482501 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial furosemide RxCUI 4603 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial moxifloxacin RxCUI 139462 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial moxifloxacin 400 MG RxCUI 330383 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Ongentys RxCUI 2362173 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial repaglinide RxCUI 73044 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial sildenafil RxCUI 136411 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial treprostinil RxCUI 343048 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor79
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.